Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Endocrine 1

Conditions

Thyroid cancer, medullary 1Carcinoma, Medullary 1

Interventions

gallium Ga 68 dotatate 690Y-octreotide, DOTA-Tyr(3)- 3Single Photon Emission Computed Tomography Computed Tomography 2Magnetic Resonance Spectroscopy 23-Iodobenzylguanidine 2trametinib 1sacubitril and valsartan sodium hydrate drug combination 1lutetium Lu 177 dotatate 1lanreotide 1corticorelin ovine 1Tomography, X-Ray Computed 1Tomography, Emission-Computed, Single-Photon 1Sitagliptin Phosphate 1Positron-Emission Tomography 1Positron Emission Tomography Computed Tomography 1Paclitaxel 1Microscopy, Electron 1Metformin 1Liraglutide 1Iodine-123 1Ga(III)-DOTATOC 1CYT-6091 168Ga-pentixafor 168Ga-NOTA-exendin-4 168Ga-FAPI 164Cu-SARTATE 16-fluorodopamine 13-fluorobenzylguanidine 12-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole 1177Lu-octreotide, DOTA(0)-Tyr(3)- 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × sacubitril and valsartan sodium hydrate drug combination × Endocrine × Clear all
NCT03647657 2022-02-10

177Lu-PP-F11N in Combination With Sacubitril for Receptor Targeted Therapy and Imaging of Metastatic Thyroid Cancer

University Hospital, Basel, Switzerland

Phase EARLY_PHASE1 Completed
8 enrolled
EndocrineHead & Neck

Thyroid cancer, medullary, Carcinoma, Medullary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡